Treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) With Atomoxetine in Young Adults and Its Effects on Functional Outcomes

Completed · Phase 4 · Has a placebo group

Conditions studied: Attention Deficit Hyperactivity Disorder

In brief

This study will evaluate atomoxetine's efficacy in treating attention-deficit/hyperactivity disorder (ADHD) symptoms and atomoxetine's effect on functional outcomes in young adults. A gatekeeper strategy will be employed for sequentially testing the secondary objectives. This study also has an observational community sample arm in which patients will complete all the efficacy measurements via web-based self reporting.

Key facts

Study ID
NCT00510276
Run by
Eli Lilly and Company
People needed
445
Starts
2007-08-01
Expected to finish
2009-02-01
Last updated by the study team
2010-04-14

Who can join

Age: 18 and older, up to 30. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.